- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Hilary Tindle Breaks Down the Nicotine Metabolite Ratio
Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, discusses the nicotine metabolite ratio (NMR) is and how it's used to help identify vulnerable individuals for lung cancer and heart disease.
The nicotine metabolite ratio (NMR) is a genetically informed biomarker that shows how nicotine is broken down by the body and varies across individuals, says Hilary Tindle, MD, MPH, associate profesor of medicine, Vanderbilt University.
Transcript
What is the NMR and how does faster metabolism contribute to a “high-risk” endophenotype?
The nicotine metabolite ratio is a genetically informed biomarker. And all it is, is the ratio or fraction of 2 breakdown products of nicotine. Nicotine in a cigarette is broken down by the liver, and nicotine has a very short half-life of only about 2 hours. But that varies a lot according to a person's genetic makeup. People who tend to break down nicotine faster are heavier smokers, they tend to smoke more, they have more difficulty quitting; therefore, they smoke for more years of their life. And therefore, they are at higher risk of smoking-related diseases, such as lung cancer and heart disease.
The nicotine metabolite ratio can be measured in blood, saliva, or even urine by a doctor. It's used in the hospital, for example, before a surgery to verify if an individual is continuing to smoke or has successfully quit smoking—but this ratio is very important for quitting. So again, people who have a higher nicotine metabolite ratio, 0.31 or higher is a commonly used cut off, those folks probably have a harder time quitting and they may even need different medication.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
